Alzhemier’s Disease Treatment

Yuki Lin

My field of research is looking at how the progression of Alzheimer's Disease might be slowed down or treated. In one clinical phase 3 trial, researchers conducted a double blinded, placebo experiment with three groups of patients. Their results showed that semagacestat does not improve cognitive abilities as compared to the placebo group. Another study conducted a double blinded, placebo experiment and found that patients who received verubecestat had worse cognitive abilities than the placebo group. Patients that have moderate or severe Alzhimer’s Disease and have been treated with donepezil for at least three months and continued as compared to those who discontinued scored higher on the Standardized Mini-Mental State Examination (SMMSE). From my research poster, people are able to see the possible treatments that are able to slow the progression of Alzheimer’s Disease; they are able to see the type of treatments that will not work as compared to those that will. I plan to continue with Ingenuity’s Research Practicum and want to find a mentor in the Department of Neuroscience at Johns Hopkins University.